Cogent Biosciences, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
COGT Nasdaq 2830 www.cogentbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cogent Biosciences, Inc.

Cogent Bioscience (COGT) Files New Drug Application For Bezuclastinib - Jul 15th, 2026 8:01 am
MEDevice Boston 2026: East Coast's Top Medical Device Conference Opens Registration for August 26-27 Event - Jul 6th, 2026 9:16 am
Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) - Jun 30th, 2026 6:00 am
Is Cogent Biosciences (COGT) ’s New Cancer Drug 100 Times More Precise Than What’s Already on the Market? - Jun 22nd, 2026 8:14 am
Cogent Biosciences' Potential Rare Blood Disease Treatment Meets Endpoints in Clinical Trial - Jun 12th, 2026 6:58 am
Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress - Jun 12th, 2026 6:01 am
Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress - Jun 12th, 2026 6:00 am
How Investors May Respond To Cogent Biosciences (COGT) Priority Review For Bezuclastinib GIST Regimen - Jun 9th, 2026 8:13 pm
Is Cogent Biosciences, Inc. (COGT) A Good Stock To Buy Now? - Jun 7th, 2026 10:42 am
This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter - May 31st, 2026 2:16 pm
Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting - May 30th, 2026 6:00 am
Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST - May 28th, 2026 6:00 am
Assessing Cogent Biosciences (COGT) Valuation After A Strong Year And Recent Share Price Pullback - May 25th, 2026 6:18 pm
What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge - May 23rd, 2026 4:40 pm
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally - May 23rd, 2026 4:33 pm
What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing - May 18th, 2026 11:44 am
Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish - May 18th, 2026 11:33 am
Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares - May 17th, 2026 1:13 pm
Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares - May 17th, 2026 1:01 pm
This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million - May 17th, 2026 12:52 pm